1. Scrip
  2. >>Business
  3. >>Strategy

Confirming Rumors, Novartis Buys AAA To Boost Oncology Business

 
• By Sten Stovall

Integrating AAA will add to Novartis' expertise in diseases associated with neuroendocrine tumors and bring it a new technology platform for treating cancer.

Acquisition
Novartis' Planned AAA Buy Targets First-In-Class Radiopharmaceuticals • Source: Shutterstock

Novartis AG is using M&A to further develop and commercialize medicines for treating neuroendocrine tumors by buying France-based Advanced Accelerator Applications SA (AAA) in an all cash transaction valued at $3.9bn.

Confirming earlier market rumors, Novartis Oct. 30 said it was offering an all-cash takeover for AAA, which makes radiopharmaceutical products containing radioisotopes used clinically for both diagnosis and therapy of tumors. AAA was spun off from Europe's physics research center CERN 15 years ago and listed on NASDAQ in 2015

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

Most Favored Nation Policy ‘Lazy, Misguided,’ But US Price Reforms Politically ‘Inevitable’

 
• By Cathy Kelly

Policy experts and pharma executives react to President Trump’s executive order on “equalizing” drug prices between the US and comparable nations at the ISPOR 2025 conference.

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.